The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment.

TIL; Th17 cells; epigenetic modifications; Cell Differentiation/immunology; Gene Expression Regulation, Neoplastic/genetics; Tumor Microenvironment/immunology; Cell Differentiation

Abstract :

[en] Th17 cells represent a subset of CD4+ T cells characterized by the master transcription factor RORγt and the production of IL-17. Epigenetic modifications such as post-translational histone modifications and DNA methylation play a key role in Th17 cell differentiation and high plasticity. Th17 cells are highly recruited in many types of cancer and can be associated with good or bad prognosis. Here, we will review the remodeling of the epigenome induced by the tumor microenvironment, which may explain Th17 cell predominance. We will also discuss the promising treatment perspectives of molecules targeting epigenetic enzymes to remodel a Th17-enriched tumor microenvironment.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Renaude, Elodie ; Université de Liège - ULiège > GIGA > GIGA Cancer - Cancer Signaling ; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, 25030, Besançon, France

Kroemer, Marie; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France

Loyon, Romain; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, 25030, Besançon, France ; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France

Binda, Delphine; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, 25030, Besançon, France

Borg, Christophe; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; Centre Hospitalier Universitaire de Besançon, Centre d'Investigation Clinique, INSERM CIC 1431, 25030, Besançon, France ; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France

Guittaut, Michaël; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; DImaCell Platform, University of Bourgogne Franche-Comté, F-25000 Besançon, France

Hervouet, Eric ; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; DImaCell Platform, University of Bourgogne Franche-Comté, F-25000 Besançon, France ; EPIGENEXP Platform, University of Bourgogne Franche-Comté, F-25000 Besançon, France

Peixoto, Paul ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Labo de recherche sur les métastases ; University of Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France ; EPIGENEXP Platform, University of Bourgogne Franche-Comté, F-25000 Besançon, France

Language :

English

Title :

The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment.

Publication date :

29 February 2020

Journal title :

International Journal of Molecular Sciences

ISSN :

1661-6596

eISSN :

1422-0067

Publisher :

MDPI, Basel, Switzerland

Volume :

Issue :

Pages :

1673

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://www.mdpi.com/1422-0067/21/5/1673/pdf

Funding text :

This work was supported by funding from institutional grants from INSERM, EFS and Univ. Bourgogne Franche-Comté and by the “Ligue Contre le Cancer”, the “Région Bourgogne Franche‐-Comté (projet d’envergure structurant C-ICI)”and european founds “Programme Interreg France‐-Suisse 2014-2020 (FEDER) – Projet R‐-TIC”.

Available on ORBi :

since 16 April 2025

Statistics

Number of views

35 (0 by ULiège)

Number of downloads

16 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Khader, S.A.; Gaffen, S.L.; Kolls, J.K. Th17 Cells at the Crossroads of Innate and Adaptive Immunity against Infectious Diseases at the Mucosa. Mucosal Immunol. 2009, 2, 403–411, doi:10.1038/mi.2009.100.
Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Turner, H.; Murphy, T.L.; Murphy, K.M.; Weaver, C.T. Interleukin 17‐-Producing CD4+ Effector T Cells Develop via a Lineage Distinct from the T Helper Type 1 and 2 Lineages. Nat. Immunol. 2005, 6, 1123–1132, doi:10.1038/ni1254.
Ivanov, I.I.; McKenzie, B.S.; Zhou, L.; Tadokoro, C.E.; Lepelley, A.; Lafaille, J.J.; Cua, D.J.; Littman, D.R. The Orphan Nuclear Receptor RORgammat Directs the Differentiation Program of Proinflammatory IL‐-17+ T Helper Cells. Cell 2006, 126, 1121–1133, doi:10.1016/j.cell.2006.07.035.
Bettelli, E.; Carrier, Y.; Gao, W.; Korn, T.; Strom, T.B.; Oukka, M.; Weiner, H.L.; Kuchroo, V.K. Reciprocal Developmental Pathways for the Generation of Pathogenic Effector TH17 and Regulatory T Cells. Nature 2006, 441, 235–238, doi:10.1038/nature04753.
Weinhold, B. Epigenetics: The Science of Change. Environ. Health Perspect. 2006, 114, A160–A167, doi:10.1289/ehp.114‐-a160.
Biswas, S.; Rao, C.M. Epigenetic Tools (The Writers, The Readers and The Erasers) and Their Implications in Cancer Therapy. Eur. J. Pharmacol. 2018, 837, 8–24, doi:10.1016/j.ejphar.2018.08.021.
Hoefig, K.P.; Heissmeyer, V. MicroRNAs Grow up in the Immune System. Curr. Opin. Immunol. 2008, 20, 281–287, doi:10.1016/j.coi.2008.05.005.
Wei, L.; Vahedi, G.; Sun, H.‐-W.; Watford, W.T.; Takatori, H.; Ramos, H.L.; Takahashi, H.; Liang, J.; Gutierrez‐-Cruz, G.; Zang, C.; et al. Discrete Roles of STAT4 and STAT6 Transcription Factors in Tuning Epigenetic Modifications and Transcription during T Helper Cell Differentiation. Immunity 2010, 32, 840– 851, doi:10.1016/j.immuni.2010.06.003.
Hirahara, K.; Vahedi, G.; Ghoreschi, K.; Yang, X.‐-P.; Nakayamada, S.; Kanno, Y.; O’Shea, J.J.; Laurence, A. Helper T‐-Cell Differentiation and Plasticity: Insights from Epigenetics. Immunology 2011, 134, 235–245, doi:10.1111/j.1365‐-2567.2011.03483.x.
Lin, F.; Meng, X.; Guo, Y.; Cao, W.; Liu, W.; Xia, Q.; Hui, Z.; Chen, J.; Hong, S.; Zhang, X.; et al. Epigenetic Initiation of the TH17 Differentiation Program Is Promoted by Cxxc Finger Protein 1. Sci. Adv. 2019, 5, eaax1608, doi:10.1126/sciadv.aax1608.
Ciofani, M.; Madar, A.; Galan, C.; Sellars, M.; Mace, K.; Pauli, F.; Agarwal, A.; Huang, W.; Parkhurst, C.N.; Muratet, M.; et al. A Validated Regulatory Network for Th17 Cell Specification. Cell 2012, 151, 289–303, doi:10.1016/j.cell.2012.09.016.
Jiang, Y.; Liu, Y.; Lu, H.; Sun, S.‐-C.; Jin, W.; Wang, X.; Dong, C. Epigenetic Activation during T Helper 17 Cell Differentiation Is Mediated by Tripartite Motif Containing 28. Nat. Commun. 2018, 9, 1424, doi:10.1038/s41467‐-018‐-03852‐-2.
Wong, L.Y.; Hatfield, J.K.; Brown, M.A. Ikaros Sets the Potential for Th17 Lineage Gene Expression through Effects on Chromatin State in Early T Cell Development. J. Biol. Chem. 2013, 288, 35170–35179, doi:10.1074/jbc.M113.481440.
Liu, Z.; Cao, W.; Xu, L.; Chen, X.; Zhan, Y.; Yang, Q.; Liu, S.; Chen, P.; Jiang, Y.; Sun, X.; et al. The Histone H3 Lysine‐-27 Demethylase Jmjd3 Plays a Critical Role in Specific Regulation of Th17 Cell Differentiation. J. Mol. Cell Biol. 2015, 7, 505–516, doi:10.1093/jmcb/mjv022.
Baumjohann, D.; Ansel, K.M. MicroRNA‐-Mediated Regulation of T Helper Cell Differentiation and Plasticity. Nat. Rev. Immunol. 2013, 13, 666–678, doi:10.1038/nri3494.
Du, C.; Liu, C.; Kang, J.; Zhao, G.; Ye, Z.; Huang, S.; Li, Z.; Wu, Z.; Pei, G. MicroRNA MiR‐-326 Regulates TH‐-17 Differentiation and Is Associated with the Pathogenesis of Multiple Sclerosis. Nat. Immunol. 2009, 10, 1252–1259, doi:10.1038/ni.1798.
Moisan, J.; Grenningloh, R.; Bettelli, E.; Oukka, M.; Ho, I.‐-C. Ets‐-1 Is a Negative Regulator of Th17 Differentiation. J. Exp. Med. 2007, 204, 2825–2835, doi:10.1084/jem.20070994.
Escobar, T.M.; Kanellopoulou, C.; Kugler, D.G.; Kilaru, G.; Nguyen, C.K.; Nagarajan, V.; Bhairavabhotla, R.K.; Northrup, D.; Zahr, R.; Burr, P.; et al. MiR‐-155 Activates Cytokine Gene Expression in Th17 Cells by Regulating the DNA‐-Binding Protein Jarid2 to Relieve Polycomb‐-Mediated Repression. Immunity 2014, 40, 865–879, doi:10.1016/j.immuni.2014.03.014.
Lee, Y.K.; Turner, H.; Maynard, C.L.; Oliver, J.R.; Chen, D.; Elson, C.O.; Weaver, C.T. Late Developmental Plasticity in the T Helper 17 Lineage. Immunity 2009, 30, 92–107, doi:10.1016/j.immuni.2008.11.005.
Harbour, S.N.; Maynard, C.L.; Zindl, C.L.; Schoeb, T.R.; Weaver, C.T. Th17 Cells Give Rise to Th1 Cells That Are Required for the Pathogenesis of Colitis. Proc. Natl. Acad. Sci. USA 2015, 112, 7061–7066, doi:10.1073/pnas.1415675112.
Obermajer, N.; Popp, F.C.; Soeder, Y.; Haarer, J.; Geissler, E.K.; Schlitt, H.J.; Dahlke, M.H. Conversion of Th17 into IL‐-17A(Neg) Regulatory T Cells: A Novel Mechanism in Prolonged Allograft Survival Promoted by Mesenchymal Stem Cell‐-Supported Minimized Immunosuppressive Therapy. J. Immunol. 2014, 193, 4988–4999, doi:10.4049/jimmunol.1401776.
Cosmi, L.; Maggi, L.; Santarlasci, V.; Capone, M.; Cardilicchia, E.; Frosali, F.; Querci, V.; Angeli, R.; Matucci, A.; Fambrini, M.; et al. Identification of a Novel Subset of Human Circulating Memory CD4(+) T Cells That Produce Both IL‐-17A and IL‐-4. J. Allergy Clin. Immunol. 2010, 125, 222–230.e1‐-4, doi:10.1016/j.jaci.2009.10.012.
Zheng, W.; Flavell, R.A. The Transcription Factor GATA‐-3 Is Necessary and Sufficient for Th2 Cytokine Gene Expression in CD4 T Cells. Cell 1997, 89, 587–596, doi:10.1016/s0092‐-8674(00)80240‐-8.
Fontenot, J.D.; Gavin, M.A.; Rudensky, A.Y. Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells. Nat. Immunol. 2003, 4, 330–336, doi:10.1038/ni904.
Mukasa, R.; Balasubramani, A.; Lee, Y.K.; Whitley, S.K.; Weaver, B.T.; Shibata, Y.; Crawford, G.E.; Hatton, R.D.; Weaver, C.T. Epigenetic Instability of Cytokine and Transcription Factor Gene Loci Underlies Plasticity of the T Helper 17 Cell Lineage. Immunity 2010, 32, 616–627, doi:10.1016/j.immuni.2010.04.016.
Wei, G.; Wei, L.; Zhu, J.; Zang, C.; Hu‐-Li, J.; Yao, Z.; Cui, K.; Kanno, Y.; Roh, T.‐-Y.; Watford, W.T.; et al. Global Mapping of H3K4me3 and H3K27me3 Reveals Specificity and Plasticity in Lineage Fate Determination of Differentiating CD4+ T Cells. Immunity 2009, 30, 155–167, doi:10.1016/j.immuni.2008.12.009.
Kanno, Y.; Vahedi, G.; Hirahara, K.; Singleton, K.; O’Shea, J.J. Transcriptional and Epigenetic Control of T Helper Cell Specification: Molecular Mechanisms Underlying Commitment and Plasticity. Annu. Rev. Immunol. 2012, 30, 707–731, doi:10.1146/annurev‐-immunol‐-020711‐-075058.
Yang, B.‐-H.; Floess, S.; Hagemann, S.; Deyneko, I.V.; Groebe, L.; Pezoldt, J.; Sparwasser, T.; Lochner, M.; Huehn, J. Development of a Unique Epigenetic Signature during in vivo Th17 Differentiation. Nucleic Acids Res. 2015, 43, 1537–1548, doi:10.1093/nar/gkv014.
Mazzoni, A.; Santarlasci, V.; Maggi, L.; Capone, M.; Rossi, M.C.; Querci, V.; De Palma, R.; Chang, H.‐-D.; Thiel, A.; Cimaz, R.; et al. Demethylation of the RORC2 and IL17A in Human CD4+ T Lymphocytes Defines Th17 Origin of Nonclassic Th1 Cells. J. Immunol. 2015, 194, 3116–3126, doi:10.4049/jimmunol.1401303.
Yoshida, N.; Kinugasa, T.; Miyoshi, H.; Sato, K.; Yuge, K.; Ohchi, T.; Fujino, S.; Shiraiwa, S.; Katagiri, M.; Akagi, Y.; et al. A High RORγT/CD3 Ratio Is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells). Ann. Surg. Oncol. 2016, 23, 919–927, doi:10.1245/s10434‐-015‐-4923‐-3.
Tosolini, M.; Kirilovsky, A.; Mlecnik, B.; Fredriksen, T.; Mauger, S.; Bindea, G.; Berger, A.; Bruneval, P.; Fridman, W.‐-H.; Pagès, F.; et al. Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer. Cancer Res. 2011, 71, 1263–1271, doi:10.1158/0008‐-5472.CAN‐-10‐-2907.
Zhou, J.; Li, X.; Wu, X.; Zhang, T.; Zhu, Q.; Wang, X.; Wang, H.; Wang, K.; Lin, Y.; Wang, X. Exosomes Released from Tumor‐-Associated Macrophages Transfer MiRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer. Cancer Immunol. Res. 2018, 6, 1578–1592, doi:10.1158/2326‐-6066.CIR‐-17‐-0479.
Zhang, J.‐-P.; Yan, J.; Xu, J.; Pang, X.‐-H.; Chen, M.‐-S.; Li, L.; Wu, C.; Li, S.‐-P.; Zheng, L. Increased Intratumoral IL‐-17‐-Producing Cells Correlate with Poor Survival in Hepatocellular Carcinoma Patients. J. Hepatol. 2009, 50, 980–989, doi:10.1016/j.jhep.2008.12.033.
He, S.; Fei, M.; Wu, Y.; Zheng, D.; Wan, D.; Wang, L.; Li, D. Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients. Int. J. Mol. Sci. 2011, 12, 7424–7437, doi:10.3390/ijms12117424.
Sfanos, K.S.; Bruno, T.C.; Maris, C.H.; Xu, L.; Thoburn, C.J.; DeMarzo, A.M.; Meeker, A.K.; Isaacs, W.B.; Drake, C.G. Phenotypic Analysis of Prostate‐-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing. Clin. Cancer Res. 2008, 14, 3254–3261, doi:10.1158/1078‐-0432.CCR‐-07‐-5164.
Ye, Z.‐-J.; Zhou, Q.; Gu, Y.‐-Y.; Qin, S.‐-M.; Ma, W.‐-L.; Xin, J.‐-B.; Tao, X.‐-N.; Shi, H.‐-Z. Generation and Differentiation of IL‐-17‐-Producing CD4+ T Cells in Malignant Pleural Effusion. J. Immunol. 2010, 185, 6348– 6354, doi:10.4049/jimmunol.1001728.
Iida, T.; Iwahashi, M.; Katsuda, M.; Ishida, K.; Nakamori, M.; Nakamura, M.; Naka, T.; Ojima, T.; Ueda, K.; Hayata, K.; et al. Tumor‐-Infiltrating CD4+ Th17 Cells Produce IL‐-17 in Tumor Microenvironment and Promote Tumor Progression in Human Gastric Cancer. Oncol. Rep. 2011, 25, 1271–1277, doi:10.3892/or.2011.1201.
Alves, J.J.P.; De Medeiros Fernandes, T.A.A.; De Araújo, J.M.G.; Cobucci, R.N.O.; Lanza, D.C.F.; Bezerra, F.L.; Andrade, V.S.; Fernandes, J.V. Th17 Response in Patients with Cervical Cancer. Oncol. Lett. 2018, 16, 6215–6227, doi:10.3892/ol.2018.9481.
Numasaki, M.; Fukushi, J.; Ono, M.; Narula, S.K.; Zavodny, P.J.; Kudo, T.; Robbins, P.D.; Tahara, H.; Lotze, M.T. Interleukin‐-17 Promotes Angiogenesis and Tumor Growth. Blood 2003, 101, 2620–2627, doi:10.1182/blood‐-2002‐-05‐-1461.
Liu, J.; Duan, Y.; Cheng, X.; Chen, X.; Xie, W.; Long, H.; Lin, Z.; Zhu, B. IL‐-17 Is Associated with Poor Prognosis and Promotes Angiogenesis via Stimulating VEGF Production of Cancer Cells in Colorectal Carcinoma. Biochem. Biophys. Res. Commun. 2011, 407, 348–354, doi:10.1016/j.bbrc.2011.03.021.
Chen, J.; Ye, X.; Pitmon, E.; Lu, M.; Wan, J.; Jellison, E.R.; Adler, A.J.; Vella, A.T.; Wang, K. IL‐-17 Inhibits CXCL9/10‐-Mediated Recruitment of CD8+ Cytotoxic T Cells and Regulatory T Cells to Colorectal Tumors. J. Immunother. Cancer 2019, 7, 324, doi:10.1186/s40425‐-019‐-0757‐-z.
Wang, L.; Yi, T.; Kortylewski, M.; Pardoll, D.M.; Zeng, D.; Yu, H. IL‐-17 Can Promote Tumor Growth through an IL‐-6‐-Stat3 Signaling Pathway. J. Exp. Med. 2009, 206, 1457–1464, doi:10.1084/jem.20090207.
Chalmin, F.; Mignot, G.; Bruchard, M.; Chevriaux, A.; Végran, F.; Hichami, A.; Ladoire, S.; Derangère, V.; Vincent, J.; Masson, D.; et al. Stat3 and Gfi‐-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity 2012, 36, 362–373, doi:10.1016/j.immuni.2011.12.019.
Allard, B.; Longhi, M.S.; Robson, S.C.; Stagg, J. The Ectonucleotidases CD39 and CD73: Novel Checkpoint Inhibitor Targets. Immunol. Rev. 2017, 276, 121–144, doi:10.1111/imr.12528.
Yip, L.; Woehrle, T.; Corriden, R.; Hirsh, M.; Chen, Y.; Inoue, Y.; Ferrari, V.; Insel, P.A.; Junger, W.G. Autocrine Regulation of T‐-Cell Activation by ATP Release and P2X7 Receptors. FASEB J. 2009, 23, 1685– 1693, doi:10.1096/fj.08‐-126458.
Schenk, U.; Frascoli, M.; Proietti, M.; Geffers, R.; Traggiai, E.; Buer, J.; Ricordi, C.; Westendorf, A.M.; Grassi, F. ATP Inhibits the Generation and Function of Regulatory T Cells through the Activation of Purinergic P2X Receptors. Sci. Signal. 2011, 4, ra12, doi:10.1126/scisignal.2001270.
He, D.; Li, H.; Yusuf, N.; Elmets, C.A.; Li, J.; Mountz, J.D.; Xu, H. IL‐-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid‐-Derived Suppressor Cells. J. Immunol. 2010, 184, 2281–2288, doi:10.4049/jimmunol.0902574.
Martin‐-Orozco, N.; Muranski, P.; Chung, Y.; Yang, X.O.; Yamazaki, T.; Lu, S.; Hwu, P.; Restifo, N.P.; Overwijk, W.W.; Dong, C. T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity 2009, 31, 787–798, doi:10.1016/j.immuni.2009.09.014.
Muranski, P.; Boni, A.; Antony, P.A.; Cassard, L.; Irvine, K.R.; Kaiser, A.; Paulos, C.M.; Palmer, D.C.; Touloukian, C.E.; Ptak, K.; et al. Tumor‐-Specific Th17‐-Polarized Cells Eradicate Large Established Melanoma. Blood 2008, 112, 362–373, doi:10.1182/blood‐-2007‐-11‐-120998.
Nuñez, S.; Saez, J.J.; Fernandez, D.; Flores‐-Santibañez, F.; Alvarez, K.; Tejon, G.; Ruiz, P.; Maldonado, P.; Hidalgo, Y.; Manriquez, V.; et al. T Helper Type 17 Cells Contribute to Anti‐-Tumour Immunity and Promote the Recruitment of T Helper Type 1 Cells to the Tumour. Immunology 2013, 139, 61–71, doi:10.1111/imm.12055.
Ducimetière, L.; Vermeer, M.; Tugues, S. The Interplay Between Innate Lymphoid Cells and the Tumor Microenvironment. Front. Immunol. 2019, 10, 2895, doi:10.3389/fimmu.2019.02895.
Loyon, R.; Jary, M.; Salomé, B.; Gomez‐-Cadena, A.; Galaine, J.; Kroemer, M.; Romero, P.; Trabanelli, S.; Adotévi, O.; Borg, C.; et al. Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation with Th1 Immune Responses. Front. Immunol. 2019, 10, 2121, doi:10.3389/fimmu.2019.02121.
Asadzadeh, Z.; Mohammadi, H.; Safarzadeh, E.; Hemmatzadeh, M.; Mahdian‐-Shakib, A.; Jadidi‐-Niaragh, F.; Azizi, G.; Baradaran, B. The Paradox of Th17 Cell Functions in Tumor Immunity. Cell. Immunol. 2017, 322, 15–25, doi:10.1016/j.cellimm.2017.10.015.
Song, Y.; Yang, J.M. Role of Interleukin (IL)‐-17 and T‐-Helper (Th)17 Cells in Cancer. Biochem. Biophys. Res. Commun. 2017, 493, 1–8, doi:10.1016/j.bbrc.2017.08.109.
Martin, F.; Apetoh, L.; Ghiringhelli, F. Controversies on the Role of Th17 in Cancer: A TGF‐-β‐-Dependent Immunosuppressive Activity? Trends Mol. Med. 2012, 18, 742–749, doi:10.1016/j.molmed.2012.09.007.
Tanaka, S.; Jiang, Y.; Martinez, G.J.; Tanaka, K.; Yan, X.; Kurosaki, T.; Kaartinen, V.; Feng, X.‐-H.; Tian, Q.; Wang, X.; et al. Trim33 Mediates the Proinflammatory Function of Th17 Cells. J. Exp. Med. 2018, 215, 1853– 1868, doi:10.1084/jem.20170779.
Bhagat, T.D.; Von Ahrens, D.; Dawlaty, M.; Zou, Y.; Baddour, J.; Achreja, A.; Zhao, H.; Yang, L.; Patel, B.; Kwak, C.; et al. Lactate‐-Mediated Epigenetic Reprogramming Regulates Formation of Human Pancreatic Cancer‐-Associated Fibroblasts. eLife 2019, 8, e50663, doi:10.7554/eLife.50663.
Yerinde, C.; Siegmund, B.; Glauben, R.; Weidinger, C. Metabolic Control of Epigenetics and Its Role in CD8+ T Cell Differentiation and Function. Front. Immunol. 2019, 10, 2718, doi:10.3389/fimmu.2019.02718.
Khan, O.; Giles, J.R.; McDonald, S.; Manne, S.; Ngiow, S.F.; Patel, K.P.; Werner, M.T.; Huang, A.C.; Alexander, K.A.; Wu, J.E.; et al. TOX Transcriptionally and Epigenetically Programs CD8+ T Cell Exhaustion. Nature 2019, 571, 211–218, doi:10.1038/s41586‐-019‐-1325‐-x.
Su, X.; Ye, J.; Hsueh, E.C.; Zhang, Y.; Hoft, D.F.; Peng, G. Tumor Microenvironments Direct the Recruitment and Expansion of Human Th17 Cells. J. Immunol. 2010, 184, 1630–1641, doi:10.4049/jimmunol.0902813.
Rezalotfi, A.; Ahmadian, E.; Aazami, H.; Solgi, G.; Ebrahimi, M. Gastric Cancer Stem Cells Effect on Th17/Treg Balance; A Bench to Beside Perspective. Front. Oncol. 2019, 9, 226, doi:10.3389/fonc.2019.00226.
Qian, X.; Gu, L.; Ning, H.; Zhang, Y.; Hsueh, E.C.; Fu, M.; Hu, X.; Wei, L.; Hoft, D.F.; Liu, J. Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL‐-23 via Tumor‐-Secreted Prostaglandin E2. J. Immunol. 2013, 190, 5894–5902, doi:10.4049/jimmunol.1203141.
Yu, Q.; Lou, X.; He, Y. Preferential Recruitment of Th17 Cells to Cervical Cancer via CCR6‐-CCL20 Pathway. PLoS ONE 2015, 10, e0120855, doi:10.1371/journal.pone.0120855.
Yu, X.; Yuan, Z.; Yang, Z.; Chen, D.; Kim, T.; Cui, Y.; Luo, Q.; Liu, Z.; Yang, Z.; Fan, X.; et al. The Novel Long Noncoding RNA U50535 Promotes Colorectal Cancer Growth and Metastasis by Regulating CCL20. Cell Death Dis. 2018, 9, 751, doi:10.1038/s41419‐-018‐-0771‐-y.
Hirota, K.; Yoshitomi, H.; Hashimoto, M.; Maeda, S.; Teradaira, S.; Sugimoto, N.; Yamaguchi, T.; Nomura, T.; Ito, H.; Nakamura, T.; et al. Preferential Recruitment of CCR6‐-Expressing Th17 Cells to Inflamed Joints via CCL20 in Rheumatoid Arthritis and Its Animal Model. J. Exp. Med. 2007, 204, 2803–2812, doi:10.1084/jem.20071397.
Chen, D.; Jiang, R.; Mao, C.; Shi, L.; Wang, S.; Yu, L.; Hu, Q.; Dai, D.; Xu, H. Chemokine/Chemokine Receptor Interactions Contribute to the Accumulation of Th17 Cells in Patients with Esophageal Squamous Cell Carcinoma. Hum. Immunol. 2012, 73, 1068–1072, doi:10.1016/j.humimm.2012.07.333.
Tokunaga, R.; Zhang, W.; Naseem, M.; Puccini, A.; Berger, M.D.; Soni, S.; McSkane, M.; Baba, H.; Lenz, H.‐ J. CXCL9, CXCL10, CXCL11/CXCR3 Axis for Immune Activation—A Target for Novel Cancer Therapy. Cancer Treat. Rev. 2018, 63, 40–47, doi:10.1016/j.ctrv.2017.11.007.
Peng, D.; Kryczek, I.; Nagarsheth, N.; Zhao, L.; Wei, S.; Wang, W.; Sun, Y.; Zhao, E.; Vatan, L.; Szeliga, W.; et al. Epigenetic Silencing of TH1‐-Type Chemokines Shapes Tumour Immunity and Immunotherapy. Nature 2015, 527, 249–253, doi:10.1038/nature15520.
Nagarsheth, N.; Peng, D.; Kryczek, I.; Wu, K.; Li, W.; Zhao, E.; Zhao, L.; Wei, S.; Frankel, T.; Vatan, L.; et al. PRC2 Epigenetically Silences Th1‐-Type Chemokines to Suppress Effector T‐-Cell Trafficking in Colon Cancer. Cancer Res. 2016, 76, 275–282, doi:10.1158/0008‐-5472.CAN‐-15‐-1938.
Johnson, A.B.; Denko, N.; Barton, M.C. Hypoxia Induces a Novel Signature of Chromatin Modifications and Global Repression of Transcription. Mutat. Res. 2008, 640, 174–179, doi:10.1016/j.mrfmmm.2008.01.001.
Johnson, A.B.; Barton, M.C. Hypoxia‐-Induced and Stress‐-Specific Changes in Chromatin Structure and Function. Mutat. Res. 2007, 618, 149–162, doi:10.1016/j.mrfmmm.2006.10.007.
Volchenkov, R.; Nygaard, V.; Sener, Z.; Skålhegg, B.S. Th17 Polarization under Hypoxia Results in Increased IL‐-10 Production in a Pathogen‐-Independent Manner. Front. Immunol. 2017, 8, 698, doi:10.3389/fimmu.2017.00698.
Mentch, S.J.; Mehrmohamadi, M.; Huang, L.; Liu, X.; Gupta, D.; Mattocks, D.; Gómez Padilla, P.; Ables, G.; Bamman, M.M.; Thalacker‐-Mercer, A.E.; et al. Histone Methylation Dynamics and Gene Regulation Occur through the Sensing of One‐-Carbon Metabolism. Cell Metab. 2015, 22, 861–873, doi:10.1016/j.cmet.2015.08.024.
Schvartzman, J.M.; Thompson, C.B.; Finley, L.W.S. Metabolic Regulation of Chromatin Modifications and Gene Expression. J. Cell Biol. 2018, 217, 2247–2259, doi:10.1083/jcb.201803061.
Miranda‐-Gonçalves, V.; Lameirinhas, A.; Henrique, R.; Jerónimo, C. Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Front. Genet. 2018, 9, 427, doi:10.3389/fgene.2018.00427.
Wong, C.C.; Qian, Y.; Yu, J. Interplay between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches. Oncogene 2017, 36, 3359–3374, doi:10.1038/onc.2016.485.
Limagne, E.; Thibaudin, M.; Euvrard, R.; Berger, H.; Chalons, P.; Végan, F.; Humblin, E.; Boidot, R.; Rébé, C.; Derangère, V.; et al. Sirtuin‐-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. Cell Rep. 2017, 19, 746–759, doi:10.1016/j.celrep.2017.04.004.
Xu, T.; Stewart, K.M.; Wang, X.; Liu, K.; Xie, M.; Ryu, J.K.; Li, K.; Ma, T.; Wang, H.; Ni, L.; et al. Metabolic Control of TH17 and Induced Treg Cell Balance by an Epigenetic Mechanism. Nature 2017, 548, 228–233, doi:10.1038/nature23475.
Morgillo, F.; Dallio, M.; Della Corte, C.M.; Gravina, A.G.; Viscardi, G.; Loguercio, C.; Ciardiello, F.; Federico, A. Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: A Comprehensive Review from Tumor Microenvironment to Gut Microbiota. Neoplasia 2018, 20, 721–733, doi:10.1016/j.neo.2018.05.002.
Bhat, M.I.; Kapila, R. Dietary Metabolites Derived from Gut Microbiota: Critical Modulators of Epigenetic Changes in Mammals. Nutr. Rev. 2017, 75, 374–389, doi:10.1093/nutrit/nux001.
Kim, H.J.; Kim, S.H.; Yun, J.‐-M. Fisetin Inhibits Hyperglycemia‐-Induced Proinflammatory Cytokine Production by Epigenetic Mechanisms. Evid. Based Complement. Alternat. Med 2012, 2012, 639469, doi:10.1155/2012/639469.
Yang, S.; Wang, B.; Guan, C.; Wu, B.; Cai, C.; Wang, M.; Zhang, B.; Liu, T.; Yang, P. Foxp3+IL‐-17+ T Cells Promote Development of Cancer‐-Initiating Cells in Colorectal Cancer. J. Leukoc. Biol. 2011, 89, 85–91, doi:10.1189/jlb.0910506.
Huang, C.; Fu, Z.‐-X. Localization of IL‐-17+Foxp3+ T Cells in Esophageal Cancer. Immunol. Investig. 2011, 40, 400–412, doi:10.3109/08820139.2011.555489.
Kryczek, I.; Wu, K.; Zhao, E.; Wei, S.; Vatan, L.; Szeliga, W.; Huang, E.; Greenson, J.; Chang, A.; Roliński, J.; et al. IL‐-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer. J. Immunol. 2011, 186, 4388–4395, doi:10.4049/jimmunol.1003251.
Li, L.; Patsoukis, N.; Petkova, V.; Boussiotis, V.A. Runx1 and Runx3 Are Involved in the Generation and Function of Highly Suppressive IL‐-17‐-Producing T Regulatory Cells. PLoS ONE 2012, 7, e45115, doi:10.1371/journal.pone.0045115.
Du, R.; Zhao, H.; Yan, F.; Li, H. IL‐-17+Foxp3+ T Cells: An Intermediate Differentiation Stage between Th17 Cells and Regulatory T Cells. J. Leukoc. Biol. 2014, 96, 39–48, doi:10.1189/jlb.1RU0114‐-010RR.
Ye, J.; Su, X.; Hsueh, E.C.; Zhang, Y.; Koenig, J.M.; Hoft, D.F.; Peng, G. Human Tumor‐-Infiltrating Th17 Cells Have the Capacity to Differentiate into IFN‐-γ+ and FOXP3+ T Cells with Potent Suppressive Function. Eur. J. Immunol. 2011, 41, 936–951, doi:10.1002/eji.201040682.
Hamaï, A.; Pignon, P.; Raimbaud, I.; Duperrier‐-Amouriaux, K.; Senellart, H.; Hiret, S.; Douillard, J.‐-Y.; Bennouna, J.; Ayyoub, M.; Valmori, D. Human T(H)17 Immune Cells Specific for the Tumor Antigen MAGE‐-A3 Convert to IFN‐-γ‐-Secreting Cells as They Differentiate into Effector T Cells in vivo. Cancer Res. 2012, 72, 1059–1063, doi:10.1158/0008‐-5472.CAN‐-11‐-3432.
Buenrostro, J.D.; Wu, B.; Litzenburger, U.M.; Ruff, D.; Gonzales, M.L.; Snyder, M.P.; Chang, H.Y.; Greenleaf, W.J. Single‐-Cell Chromatin Accessibility Reveals Principles of Regulatory Variation. Nature 2015, 523, 486–490, doi:10.1038/nature14590.
Borst, J.; Ahrends, T.; Bąbała, N.; Melief, C.J.M.; Kastenmüller, W. CD4+ T Cell Help in Cancer Immunology and Immunotherapy. Nat. Rev. Immunol. 2018, 18, 635–647, doi:10.1038/s41577‐-018‐-0044‐-0.
Peixoto, P.; Renaude, E.; Boyer‐-Guittaut, M.; Hervouet, E. Epigenetics, a Key Player of Immunotherapy Resistance. CDR 2018, 1, 219–229, doi:10.20517/cdr.2018.17.
Bretz, A.C.; Parnitzke, U.; Kronthaler, K.; Dreker, T.; Bartz, R.; Hermann, F.; Ammendola, A.; Wulff, T.; Hamm, S. Domatinostat Favors the Immunotherapy Response by Modulating the Tumor Immune Microenvironment (TIME). J. Immunother. Cancer 2019, 7, 294, doi:10.1186/s40425‐-019‐-0745‐-3.
Qin, Y.; Vasilatos, S.N.; Chen, L.; Wu, H.; Cao, Z.; Fu, Y.; Huang, M.; Vlad, A.M.; Lu, B.; Oesterreich, S.; et al. Inhibition of Histone Lysine‐-Specific Demethylase 1 Elicits Breast Tumor Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade. Oncogene 2019, 38, 390–405, doi:10.1038/s41388‐-018‐-0451‐-5.
Hong, Y.K.; Li, Y.; Pandit, H.; Li, S.; Pulliam, Z.; Zheng, Q.; Yu, Y.; Martin, R.C.G. Epigenetic Modulation Enhances Immunotherapy for Hepatocellular Carcinoma. Cell. Immunol. 2019, 336, 66–74, doi:10.1016/j.cellimm.2018.12.010.
Charmsaz, S.; Collins, D.M.; Perry, A.S.; Prencipe, M. Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference. Cancers 2019, 11, 1125, doi:10.3390/cancers11081125.
Chiappinelli, K.B.; Strissel, P.L.; Desrichard, A.; Li, H.; Henke, C.; Akman, B.; Hein, A.; Rote, N.S.; Cope, L.M.; Snyder, A.; et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via DsRNA Including Endogenous Retroviruses. Cell 2015, 162, 974–986, doi:10.1016/j.cell.2015.07.011.
Khan, A.N.H.; Gregorie, C.J.; Tomasi, T.B. Histone Deacetylase Inhibitors Induce TAP, LMP, Tapasin Genes and MHC Class I Antigen Presentation by Melanoma Cells. Cancer Immunol. Immunother. 2008, 57, 647–654, doi:10.1007/s00262‐-007‐-0402‐-4.
Sun, T.; Li, Y.; Yang, W.; Wu, H.; Li, X.; Huang, Y.; Zhou, Y.; Du, Z. Histone Deacetylase Inhibition Up‐-Regulates MHC Class I to Facilitate Cytotoxic T Lymphocyte‐-Mediated Tumor Cell Killing in Glioma Cells. J. Cancer 2019, 10, 5638–5645, doi:10.7150/jca.34471.
Shen, L.; Ciesielski, M.; Ramakrishnan, S.; Miles, K.M.; Ellis, L.; Sotomayor, P.; Shrikant, P.; Fenstermaker, R.; Pili, R. Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models. PLoS ONE 2012, 7, e30815, doi:10.1371/journal.pone.0030815.
Orillion, A.; Hashimoto, A.; Damayanti, N.; Shen, L.; Adelaiye‐-Ogala, R.; Arisa, S.; Chintala, S.; Ordentlich, P.; Kao, C.; Elzey, B.; et al. Entinostat Neutralizes Myeloid‐-Derived Suppressor Cells and Enhances the Antitumor Effect of PD‐-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin. Cancer Res. 2017, 23, 5187–5201, doi:10.1158/1078‐-0432.CCR‐-17‐-0741.
Li, Q.; Zou, J.; Wang, M.; Ding, X.; Chepelev, I.; Zhou, X.; Zhao, W.; Wei, G.; Cui, J.; Zhao, K.; et al. Critical Role of Histone Demethylase Jmjd3 in the Regulation of CD4+ T‐-Cell Differentiation. Nat. Commun. 2014, 5, 5780, doi:10.1038/ncomms6780.
Ye, Q.; Zhang, M.; Wang, Y.; Fu, S.; Han, S.; Wang, L.; Wang, Q. Sirtinol Regulates the Balance of Th17/Treg to Prevent Allograft Rejection. Cell Biosci. 2017, 7, 55, doi:10.1186/s13578‐-017‐-0182‐-2.
Chadha, S.; Wang, L.; Hancock, W.W.; Beier, U.H. Sirtuin‐-1 in Immunotherapy: A Janus‐-Headed Target. J. Leukoc. Biol. 2019, 106, 337–343, doi:10.1002/JLB.2RU1118‐-422R.
Lim, H.W.; Kang, S.G.; Ryu, J.K.; Schilling, B.; Fei, M.; Lee, I.S.; Kehasse, A.; Shirakawa, K.; Yokoyama, M.; Schnölzer, M.; et al. SIRT1 Deacetylates RORγt and Enhances Th17 Cell Generation. J. Exp. Med. 2015, 212, 607–617, doi:10.1084/jem.20132378.
Akimova, T.; Xiao, H.; Liu, Y.; Bhatti, T.R.; Jiao, J.; Eruslanov, E.; Singhal, S.; Wang, L.; Han, R.; Zacharia, K.; et al. Targeting Sirtuin‐-1 Alleviates Experimental Autoimmune Colitis by Induction of Foxp3+ T‐-Regulatory Cells. Mucosal Immunol. 2014, 7, 1209–1220, doi:10.1038/mi.2014.10.
Zhang, X.; Han, S.; Kang, Y.; Guo, M.; Hong, S.; Liu, F.; Fu, S.; Wang, L.; Wang, Q.X. SAHA, an HDAC Inhibitor, Synergizes with Tacrolimus to Prevent Murine Cardiac Allograft Rejection. Cell. Mol. Immunol. 2012, 9, 390–398, doi:10.1038/cmi.2012.28.